Asymptomatic and oligosymptomatic states of dysferlinopathy.

Sergey N Bardakov, Vadim A Tsargush, Sergey A Kurbatov, Zoya R Umakhanova, Artur A Isaev, Roman V Deev, Pierre G Carlier, Vladimir S Kaimonov, Elizaveta V Musatova, Konstantin A Blagodatskikh, Aleksandra A Tveleneva, Yana V Sofronova, Vasiliy M Suslov, Ivan A Yakovlev

Journal: Journal of neuromuscular diseases 2025;11(6):1283-1294

PMID: 39973465

Abstract

Dysferlinopathy is a phenotypically heterogeneous, inherited, progressive muscular dystrophy caused by mutations in the gene. Dysferlinopathy is marked by elevated serum creatine kinase (CK) and can in some cases manifest as hyperCKemia in asymptomatic or low-symptom states. Here, we describe the clinical signs and symptoms and laboratory and imaging results with quantitative MRI analysis of eight pediatric patients at asymptomatic and oligosymptomatic states of dysferlinopathy (aged 3-14 years). Seven of them with a same homozygous mutation and one with a compound heterozygous mutation in the gene. Based on this case series, we propose two stages of dysferlinopathy disease progression. The first state is asymptomatic hyperCKemia laboratory syndrome of myocytolysis, which is marked by an increase in CK (>1.5 times the upper limit of normal (ULN)) and lactic dehydrogenase (LDH). Second state (oligosymptomatic): increasing CK (2.7-12.6 × ULN), LDH, alanine aminotransferase (ALT), and myoglobin; minimal or moderate signs of fatty muscle infiltration, displacement of the center of support to the back of the foot during plantography; slight afterload fatigue of the calf muscles; slight decrease in muscle strength (imperceptible to the patient) and decrease in Achilles reflexes. Taken together, isolated hyperCKemia (asymptomatic stage) and oligosymptomatic patients form a single continuum of pre-manifest cases.

Address: S.M. Kirov Military Medical Academy, St. Petersburg, Russia.; A.P. Avtsyn Research Institute of Human Morphology of Federal state budgetary scientific institution "Petrovsky National Research Centre of Surgery", Ministry of Science and Higher Education of Russia, Moscow, Russia.; Artgen Biotech PJSC, Moscow, Russia.; Belgorod National Research University, Belgorod, Russiaxs.; Belgorod National Research University, Belgorod, Russiaxs.; Genetico, Moscow, Russia.; Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russia.; Neuromuscular Disease Reference Center, University of Liege, and Department of Neurology, St. Luc University Hospital, Brussels, Belgium.; Research Institute of Experimental Biology and Medicine, Voronezh N.N. Burdenko State Medical University, Voronezh, Russia.; Artgen Biotech PJSC, Moscow, Russia.; Genetico, Moscow, Russia.; Genotarget LLC, Skolkovo Innovation Centre, Moscow, Russia.; Dagestan State Medical University, Makhachkala, Russia.; Artgen Biotech PJSC, Moscow, Russia.; Genetico, Moscow, Russia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.